



Express Mail No.: EL 477 034 620 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No. 7010

Application No.: 09/724,531

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: To be assigned

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES
FOR PROPHYLAXIS AND
TREATMENT

Attorney Docket No.: 10271-021-999

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references AA-DI listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references AA-DC are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since Applicants believe that this Information Disclosure Statement is being submitted prior to the first Office Action on merits, no fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date June 20, 2002

Anthony M. Insogna 35,203
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

by Margaret B. Brivencia
Reg No. 40,900



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-021-999

APPLICATION NO.

09/724,531

APPLICANT

Young et al.

FILING DATE

November 28, 2000

GROUP

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,526,938	7/2/85	Churchill et al.			
	AB	4,880,078	11/14/89	Inoue et al.			
	AC	5,128,326	7/7/92	Balazs et al.			
	AD	5,290,540	3/1/94	Prince et al.			
	AE	5,679,377	10/21/97	Bernstein et al.			
	AF	5,824,307	10/20/98	Johnson			
	AG	5,855,913	1/5/99	Hanes et al.			
	AH	5,874,064	2/23/99	Edwards et al.			
	AI	5,912,015	6/15/99	Bernstein et al.			
	AJ	5,916,597	6/29/99	Lee et al.			
	AK	5,934,272	8/10/99	Lloyd et al.			
	AL	5,985,309	11/16/99	Edwards et al.			
	AM	5,985,320	11/16/99	Edwards et al.			
	AN	5,989,463	11/23/99	Tracy et al.			
	AO	6,019,968	2/1/00	Platz et al.			
	DD	5,811,524	9/22/98	Brams et al.			
	AP	09/158,120		"Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus"			9/21/98
	AQ	09/865,499		Epitope Based Vaccine for Respiratory Syncytial Virus F-Protein"			5/25/01
	AR	09/848,390		"Combination Therapy of Respiratory Diseases using Antibodies"			5/3/01
	AS	09/848,377		"Combination Therapy of Respiratory Diseases Using Antibodies and Anti-Inflammatory Agents"			5/3/01
	AT	09/797,760		"Methods of Enhancing Activity of Vaccines and Vaccine Compositions"			3/2/01
	AU	09/796,848		"High Potency Recombinant Antibodies and Methods for Producing Them"			3/1/01
	AV	09/781,052		"Antibody Gene Therapy with Adeno-Associated Viral Vectors"			2/9/01
	AW	09/771,415		"Ultra High Affinity Neutralizing Antibodies"			1/26/01
	AX	60/186,252		"High Potency Recombinant Antibodies and Methods for Producing Them"			3/1/00
	AY	60/168,426		"High Potency Recombinant Antibodies and Methods for Producing Them"			1/27/00
	DD	5,811,524	0/22/98	Brams et al.			
	DE	5,840,298	11/24/98	Brams et al.			

	DF	5,866,125	2/2/99	Brams et al.			
	DG	5,955,364	9/21/99	Brams et al.			
	DH	5,958,765	9/28/99	Brams et al.			
	DI	2002 0001 798	1/3/02	Brams et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AZ	WO 91/05548	5/2/91	PCT				
	BA	WO 92/19244	11/12/92	PCT				
	BB	WO 96/20698	7/11/96	PCT				
	BC	WO 97/34631	9/25/97	PCT				
	BD	WO 97/32572	9/12/97	PCT				
	BE	WO 97/44013	11/27/97	PCT				
	BF	WO 98/31346	7/23/98	PCT				
	BG	WO 99/15154	4/01/99	PCT				
	BH	WO 99/20253	4/29/99	PCT				
	BI	WO 99/66903	12/29/99	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	BJ	Abman et al., 1988, "Role of Respiratory Syncytial Virus in Early Hospitalizations for Respiratory Distress of Young Infants With Cystic Fibrosis", J Pediatr. 113(5):826-30.
	BK	American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. 1993 Sep;92(3):501-4.
	BL	Beeler et al., 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function", J Virol. 63(7):2941-50.
	BM	Bentley et al., 1980, "Human immunoglobulin variable region genes— DNA Sequences of Two V Kappa Genes and a Pseudogene", Nature 288: 5194-5198
	BN	Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application" Pro. Int'l Symp. Control. Rel Bioact. Mater. 24: 853-854
	BO	Evans, A.S., 1989, Viral Infections of Humans, Epidemiology and Control, 3 rd ed., 525-44
	BP	Falsey et al., 1991, "Noninfluenza Respiratory Virus Infection in Long-Term Care Facilities", Infect Control Hosp Epidemiol. 12(10):602-8..
	BQ	Feigen et al., 1987, Textbook of Pediatric Infectious Diseases, WB Saunders, Philadelphia, pp. 1653-1675
	BR	Garvie et al., 1980, "Outbreak of Respiratory Syncytial Virus Infection in the Elderly", Br Med J. 281(6250):1253-4.
	BS	Glezen et al., 1981, "Risk of Respiratory Syncytial Virus Infection for Infants From Low-Income Families in Relationship to Age, Sex, Ethnic Group, and Maternal Antibody Level", J Pediatr. 98(5):708-15.
	BT	Groothuis et al., 1988, "Respiratory Syncytial Virus Infection in Children with Bronchopulmonary Dysplasia", Pediatrics. 82(2):199-203.
	BU	Groothuis et al., 1993, "Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-risk Infants and Young Children", The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 329(21):1524-30.
	BV	Hall et al., 1979, "Neonatal Respiratory Syncytial Virus Infection", N Engl J Med. 300(8):393-6.
	BW	Hall, C.B., 1993, Respiratory Syncytial : What We Know Now", Contemp. Pediatrics, 10: 92-110.
	BX	Hemming et al., 1985, "Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model", J Infect Dis. 152(5):1083-7.

	BY	Henderson et al., 1979, "Respiratory Syncytial-Virus Infections, Reinfections and Immunity. A Prospective, Longitudinal Study in Young Children", <i>N Engl J Med</i> , 300(10):530-4.
	BZ	Hertz et al., 1989, "Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients With Bone Marrow Transplants: a Clinical Approach and Review of the Literature", <i>Medicine (Baltimore)</i> , 68(5):269-81.
	CA	Howard et al., 1989, "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits", <i>J Neurosurg.</i> 71(1):105-12.
	CB	Johnson et al., 1987, "The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins", <i>Proc Natl Acad Sci U S A.</i> 84(16):5625-9.
	CC	Johnson et al., 1987, "Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent <i>In Vitro</i> and <i>In Vivo</i> Activity Against Respiratory Syncytial Virus", <i>J Infect Dis.</i> 176(5):1215-24.
	CD	Kapikian et al., 1969, "An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine", <i>Am J Epidemiol.</i> 89(4):405-21
	CE	Kim et al., 1969, "Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine", <i>Am J Epidemiol.</i> 89(4):422-34
	CF	Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", <i>Proc. Int'l. Symp. Control Rel. Bioact. Mater.</i> 24:759-760
	CG	Lamprecht et al., 1976, "Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus", <i>J Infect Dis.</i> 134(3):211-7.
	CH	Levy et al., 1985, "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-release Diphosphonate", <i>Science.</i> 228(4696):190-2.
	CI	MacDonald et al., 1982, "Respiratory Syncytial Viral Infection in Infants With Congenital Heart Disease", <i>N Engl J Med.</i> 307(7):397-400.
	CJ	Morell et al., eds, 1986, <i>Clinical Use of Intravenous Immunoglobulins</i> , Academic Press, London, pp. 285-94.
	CK	Murphy et al., 1991, "Effect of Passive Antibody on the Immune Response of Cotton Rats to Purified F and G HG Glycoproteins of Respiratory Syncytial Virus (RSV)", <i>Vaccine.</i> 9(3):185-9.
	CL	Murphy et al., 1988, "Passive Transfer of Respiratory Syncytial Virus (RSV) Antiserum Suppresses The Immune Response to the RSV Fusion (F) and Large (G) Glycoproteins Expressed By Recombinant Vaccinia Viruses", <i>J Virol.</i> 62(10):3907-10.
	CM	Murphy and Hall, 1994, "An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines", <i>Virus Res.</i> 32(1):13-36.
	CN	Navas et al., 1992, "Improved Outcome of Respiratory Syncytial Virus Infection in a High-Risk Hospitalized Population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada", <i>J Pediatr.</i> 121(3):348-54.
	CO	Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained Release Gel", <i>Radiotherapy and Oncology</i> 39: 179-89
	CP	Ogra et al., 1988, "Respiratory Syncytial Virus Infection and the Immunocompromised Host", <i>Pediatr Infect Dis J.</i> 1988 Apr;7(4):246-9.
	CQ	Palvizumab et al., 1998, "A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants", <i>The IMPact-RSV Study Group. Pediatrics.</i> 102(3 Pt 1):531-7.
	CR	Pohl et al., 1992, "Respiratory Syncytial Virus Infections in Pediatric Liver Transplant Recipients", <i>J Infect Dis.</i> 165(1):166-9.
	CS	Press et al., 1970, "The Amino Acid Sequences of the Fd Fragments of Two Human Gamma-1 Heavy chains", <i>Biochem J.</i> 117(4):641-60
	CT	Prince et al., 1985, "Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus Infection in the Cotton rat", <i>Virus Res.</i> 3(3):193-206.
	CU	Prince et al., 1983, "Mechanisms of Immunity to Respiratory Syncytial Virus in Cotton Rats", <i>Infect Immun.</i> 42(1):81-7.
	CV	Prince et al., 1990, "Mechanism of Antibody-mediated Viral Clearance in Immunotherapy of Respiratory Syncytial Virus Infection of Cotton Rats", <i>J Virol.</i> 64(6):3091-2.
	CW	Prince et al., 1985, "Quantitative Aspects of Passive Immunity to Respiratory Syncytial Virus Infection in Infant Cotton Rats", <i>J Virol.</i> 55(3):517-20.
	CX	Ruuskanen et al., 1993, "Respiratory syncytial virus", <i>Curr Probl Pediatr.</i> 23(2):50-79.

	CY	Saudek et al., 1989, "A Preliminary Trial of the Pprogrammable Implantable Medication System for Insulin Delivery. N Engl J Med. 321(9):574-9.
	CZ	Sefton, 1987, "Implantable Pumps", CRC Crit. Ref. Biomed. Eng. 14:20
	DA	Smith t al., 1991, "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection", N Engl J Med. 325(1):24-9.
	DB	Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions", PDA Journal of Pharmaceutical Science & Technology 50: 372-97
	DC	Walsh et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection", J Infect Dis. 155(6):1198-204.
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

